Fetching results...
0 items found

A0272: 3-year outcomes from the prospective ‘MRIAS’ trial: A novel active surveillance protocol which incorporates multiparametric MRI to reduce frequency of biopsy in men with prostate cancer

Dr. P.N. (Paul) Doan
Doan P.N.1, Scheltema M.J.2, Amin A.A.1, Shnier R.3, Geboers B.1, Gondoputro W.1, Moses D.4, Van Leeuwen P.J.5, Haynes A-M.1, Matthews J.6, Brenner P.7, O'Neill G.7, Yuen C.7, Delprado W.8, Stricker P.1, Thompson J.1
1Garvan Institute of Medical Research, Clinical Prostate Cancer Research Group, Sydney, Australia, 2Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, 3I-MED Radiology, Dept. of MRI, Sydney, Australia, 4University of New South Wales, School of Medicine, Sydney, Australia, 5Antoni van Leeuwenhoek Nederlands Kanker Instituut, Dept. of Urology, Amsterdam, The Netherlands, 6St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, 7St. Vincent's Clinic, Dept. of Urology, Sydney, Australia, 8Douglas Hanly Moir Pathology, Dept. of Uropathology, Sydney, Australia
37th Annual EAU Congress
Date – Time - Location
02 July 2022, 10:45 - 12:15, Yellow Area, Room Forum
Abstract Session 15 - Active surveillance and modern diagnostics
Prostate Cancer, localised - Treatment, Active Surveillance
  • © 2022 European Association of Urology
  • Disclaimer